Plasma levels of soluble amyloid precursor protein beta in symptomatic 
Alzheimer's disease

Alexopoulos, Panagiotis; Gleixner, Lena-Sophie; Werle, Lukas; Buhl, Felix; Thierjung, Nathalie; Giourou, Evangelia; Kagerbauer, Simone M.; Gourzis, Philippos; Kuebler, Hubert; Grimmer, Timo; Yakushev, Igor; Martin, Jan; Kurz, Alexander; Perneczky, Robert

doi:10.1007/s00406-017-0815-9

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Plasma levels of soluble amyloid precursor protein beta in symptomatic Alzheimer's disease

MPS-Authors

/persons/resource/persons202228

Werle, Lukas
Max Planck Institute of Psychiatry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Alexopoulos, P., Gleixner, L.-S., Werle, L., Buhl, F., Thierjung, N., Giourou, E., et al. (2018). Plasma levels of soluble amyloid precursor protein beta in symptomatic Alzheimer's disease. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 268(5), 519-524. doi:10.1007/s00406-017-0815-9.

Cite as: https://hdl.handle.net/21.11116/0000-0003-5DF1-5

Abstract

The established biomarkers of Alzheimer's disease (AD) require invasive endeavours or presuppose sophisticated technical equipment. Consequently, new biomarkers are needed. Here, we report that plasma levels of soluble amyloid precursor protein beta (sAPP beta), a protein of the initial phase of the amyloid cascade, were significantly lower in patients with symptomatic AD (21 with mild cognitive impairment due to AD and 44 with AD dementia) with AD-typical cerebral hypometabolic pattern compared with 27 cognitively healthy elderly individuals without preclinical AD. These findings yield further evidence for the potential of sAPP beta in plasma as an AD biomarker candidate.